Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...

Just a few days after Biogen abandoned its tau-targeting Alzheimer's disease candidate gosuranemab, Bristol-Myers Squibb has opted into a rival drug, paying $80 million for rights to Prothena's ...

Your full guide to this year's GCSE exams in England, Wales and Northern Ireland.

News Education Operation Sindoor a military success, tech breakthrough, political message all rolled into one: NCERT’s new module Operation Sindoor a military success, tech breakthrough, political ...